A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients.
暂无分享，去创建一个
R. Foà | M. Boccadoro | S. Bringhen | P. Musto | F. Pisani | F. Cavallo | A. Palumbo | A. Liberati | M. Petrucci | E. Calabrese | A. Falcone | P. Pregno | T. Caravita | C. Cangialosi | V. Lauta | M. Grasso | A. Nozza | M. Montanaro | P. Omedè